Questionnaire Survey of Recommendations on “Pharmacy Expert Consensus on the Therapeutic Drug Monitoring of Antitumor Biosimilars（ 2020 Edition） ”

CHEN Wenqian; LI Bo; QIN Wangjun; LI Shu; ZHANG Xianglin

doi:10.14009/j.issn.1672-2124.2020.05.002

您当前的位置：

首页 >

文章列表页 >

Questionnaire Survey of Recommendations on “Pharmacy Expert Consensus on the Therapeutic Drug Monitoring of Antitumor Biosimilars（ 2020 Edition） ”

更新时间：2022-10-08

- Questionnaire Survey of Recommendations on “Pharmacy Expert Consensus on the Therapeutic Drug Monitoring of Antitumor Biosimilars（ 2020 Edition） ”
- Vol. 20, Issue 5, Pages: 518-520(2020)
- 作者机构：
  
  中日友好医院药学部
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2020.05.002
  CLC： R979.1
- Published：2020，
扫描看全文
[1]陈文倩,李博,覃旺军,李沭,张相林.《抗肿瘤生物类似药治疗药物监测药学专家共识(2020版)》推荐意见的问卷调查[J].中国医院用药评价与分析,2020,20(05):518-520+525.

CHEN Wenqian, LI Bo, QIN Wangjun, et al. Questionnaire Survey of Recommendations on “Pharmacy Expert Consensus on the Therapeutic Drug Monitoring of Antitumor Biosimilars（ 2020 Edition） ”. [J]. 20(5):518-520(2020)
[1]陈文倩,李博,覃旺军,李沭,张相林.《抗肿瘤生物类似药治疗药物监测药学专家共识(2020版)》推荐意见的问卷调查[J].中国医院用药评价与分析,2020,20(05):518-520+525. DOI： 10.14009/j.issn.1672-2124.2020.05.002.

CHEN Wenqian, LI Bo, QIN Wangjun, et al. Questionnaire Survey of Recommendations on “Pharmacy Expert Consensus on the Therapeutic Drug Monitoring of Antitumor Biosimilars（ 2020 Edition） ”. [J]. 20(5):518-520(2020) DOI： 10.14009/j.issn.1672-2124.2020.05.002.

摘要

目的:《抗肿瘤生物类似药治疗药物监测药学专家共识（2020版）》由中国药理学会与中日友好医院共同发起

是我国首部对抗肿瘤生物类似药治疗药物监测工作进行指导的专家共识。本文在制定过程中对外审专家意见调研力求客观、全面

探索专业性、规范性融合的共识制定方法。方法:对专家共识中的推荐意见进行独立外审

以在线问卷形式定向征集相关领域专家意见

收集推荐程度等级结果。结果:共收集到72份有效问卷

其中全部推荐意见的强推荐占比均>50%。结论:参与调研专家对本共识的认同度较高

问卷调研的方法可作为共识制定外审过程中意见征集的方法。

Abstract

OBJECTIVE: "Pharmacy Expert Consensus on the Therapeutic Drug Monitoring of Antitumor Biosimilars（ 2020 Edition） " is jointly issued by Chinese Pharmacological Society and China-Japan Friendship Hospital

which is the first expert consensus in China to guide the therapeutic drug monitoring of antitumor biosimilars.During the consensus formulation process

this paper strives to be objective and comprehensive in investigating the opinions of experts in external evaluation

and explores the development method of professional and normative consensus. METHODS: Independent external investigation was carried out on the recommendation opinions in the expert consensus

and experts’ recommendations in relevant fields were collected in the form of online questionnaire

and the results of recommendation degree were collected. RESULTS: A total of 72 valid questionnaires were collected

of which the proportion of strong recommendation was more than 50%. CONCLUSIONS: The experts involved in the survey have a high degree of recognition for this consensus

and questionnaire survey can be used as a method of opinion collection in the process of consensus formulation and external evaluation.

关键词

抗肿瘤生物类似药问卷调查治疗药物监测专家共识

Keywords

Antitumor biosimilarsQuestionnaire surveyTherapeutic drug monitoringExpert consensus

references

查看原文

Views

250

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Interpretation of “Pharmacy Expert Consensus on the Therapeutic Drug Monitoring of Antitumor Biosimilars（2020 Edition） ”

Progress of Therapeutic Drug Monitoring of Biologic Agents for Rheumatic and Immunological Diseases

Blood Concentration Monitoring of Digoxin in A Hospital and Its Influencing Factors

Expert Consensus on the Chemotherapy Principles of Lung Cancer

Effect of Different Preservation Conditions on Monitoring the Blood Concentration of Cyclosporine by Chemiluminescence Microparticle Immunoassay

Related Author

Chinese Pharmacological Society

China-Japan Friendship Hospital

XIONG Xiaofu

TIAN Xueke

QIN Zhiying

YANG Jing

ZHANG Xiaojian

Related Institution

中日友好医院

中国药理学会中日友好医院

Japan Friendship Hospital

Henan Engineering Research Center for Application ＆ Translation of Precision Clinical Pharmacy

Henan Key Laboratory of Precision Clinical Pharmacy

⁰